As of 2025-05-21, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -9.90. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 392.86 mil USD. TBPH's TTM EBITDA according to its financial statements is -39.69 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.7x - 7.1x | 6.0x |
| Forward P/E multiples | 4.6x - 7.3x | 6.0x |
| Fair Price | (2.14) - (4.01) | (3.19) |
| Upside | -122.6% - -142.5% | -133.8% |
| Date | EV/EBITDA |
| 2025-05-12 | -9.08 |
| 2025-05-09 | -9.31 |
| 2025-05-08 | -10.46 |
| 2025-05-07 | -10.58 |
| 2025-05-06 | -10.70 |
| 2025-05-05 | -10.96 |
| 2025-05-02 | -11.06 |
| 2025-05-01 | -11.08 |
| 2025-04-30 | -10.30 |
| 2025-04-29 | -9.96 |
| 2025-04-28 | -10.28 |
| 2025-04-25 | -10.28 |
| 2025-04-24 | -10.01 |
| 2025-04-23 | -9.90 |
| 2025-04-22 | -9.72 |
| 2025-04-21 | -9.49 |
| 2025-04-17 | -8.85 |
| 2025-04-16 | -8.82 |
| 2025-04-15 | -8.86 |
| 2025-04-14 | -8.99 |
| 2025-04-11 | -8.57 |
| 2025-04-10 | -8.56 |
| 2025-04-09 | -8.74 |
| 2025-04-08 | -8.47 |
| 2025-04-07 | -8.59 |
| 2025-04-04 | -8.63 |
| 2025-04-03 | -9.04 |
| 2025-04-02 | -9.34 |
| 2025-04-01 | -9.36 |
| 2025-03-31 | -9.24 |
| 2025-03-28 | -9.62 |
| 2025-03-27 | -9.72 |
| 2025-03-26 | -9.71 |
| 2025-03-25 | -9.72 |
| 2025-03-24 | -9.82 |
| 2025-03-21 | -9.82 |
| 2025-03-20 | -9.78 |
| 2025-03-19 | -9.92 |
| 2025-03-18 | -9.60 |
| 2025-03-17 | -9.77 |
| 2025-03-14 | -9.62 |
| 2025-03-13 | -9.68 |
| 2025-03-12 | -9.88 |
| 2025-03-11 | -9.70 |
| 2025-03-10 | -9.91 |
| 2025-03-07 | -10.00 |
| 2025-03-06 | -10.23 |
| 2025-03-05 | -10.24 |
| 2025-03-04 | -9.46 |
| 2025-03-03 | -9.52 |